Biblio Discovery — Demo Discovery Service

4 hasil untuk "Mohammad M Mohammad"

Menampilkan 1–4 · 1,29 detik · RSS

  1. Artikel Jurnal Teks lengkap

    8- LAPAROSCOPIC CHOLECYSTECTOMY IN SICKLE CELL DISEASE: IS IT A SAFE PROCEDURE?

    Hashim S Alkhayat; Jassim H Salim; Mohammad M Mohammad dkk.

    Basrah Journal of Surgery, Vol. 17 No. 1 · 2011 · Inggris · DOAJ

    Salim M Albassam*, Mohammad M Mohammad@, Jassim H Salim@& Hashim S Alkhayat@ *Department of surgery, Basrah Medical College, Iraq. @Department of surgery, Basrah General Hospital, Iraq. Correspondence to: Dr. Salim M Albassam, e-mail: albassamsalim@yahoo.ca Abbreviation: Hb= Hemoglobin. ACS = Acute…

  2. Artikel Jurnal

    A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

    Bora Lim; Angela Marx; Megumi Kai dkk.

    Therapeutic Advances in Medical Oncology, Vol. 17 · 2025 · Inggris · DOAJ Scopus

    Background: Inflammatory breast cancer (IBC) is rare but aggressive, characterized by the rapid onset of diffuse skin erythema, edema, tenderness, induration, and fast metastasis. Both hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+) are associated with inferior…

  3. Artikel Jurnal

    Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer

    Sara Corvigno; Jun Yao; Amma Asare dkk.

    Frontiers in Oncology, Vol. 15 · 2025 · Inggris · DOAJ Scopus

    IntroductionClonal hematopoiesis (CH) is characterized by the presence of hematopoietic stem cells (HSCs) with the potential of clonally expanding and giving rise to hematological malignancies. Clonal hematopoiesis of indeterminate potential (CHIP) is the outgrowth of a single HSC clone with an…

  4. Artikel Jurnal

    Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

    Melinda Soeung; Xinmiao Yan; Ciro Zanca dkk.

    Nature Communications, Vol. 16 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Therapeutic options for patients with renal medullary carcinoma (RMC) are limited. Here we report the results of a phase II clinical trial (NCT03274258) of anti-PD1 nivolumab plus anti-CTLA4 ipilimumab in patients with RMC, with objective response rate as primary outcome. Enrollment was…